Halozyme Therapeutics | HALO - Capitale Ordinario





Capitale Ordinario Cambiamento Data
Acadia Pharmaceuticals USD 171.09M 1.9M 2026-03
Agios Pharmaceuticals USD 59.34M 892K 2026-03
Alnylam Pharmaceuticals USD 133.73M 290K 2026-06
Amarin USD 20.81M 13K 2025-12
Amgen USD 541M 1000K 2026-06
Baxter International USD 517M 549K 2026-06
Cara Therapeutics USD 9.38M 2.01K 2026-03
Cytokinetics USD 124.43M 2.17M 2026-03
DBV Technologies USD 235.6M 98.78M 2025-12
Eli Lilly USD 943.5M 3.33M 2026-03
Halozyme Therapeutics USD 114.04M 4.48M 2026-06
Intrexon USD 0 0 2024-06
Ionis Pharmaceuticals USD 165.64M 265K 2026-06
MannKind USD 309.91M 1M 2026-06
Minerva Neurosciences USD 1000 0 2024-09
Nektar Therapeutics USD 29.47M 9.09M 2026-03
Pfizer USD 5.7B 0 2026-06
Rigel Pharmaceuticals USD 17K 158K 2024-06
United Therapeutics USD 42.68M 521K 2026-06
Vanda Pharmaceuticals USD 58K 0 2024-12